Tannic acid as a natural antioxidant compound: Discovery of a potent metabolic enzyme inhibitor for a new therapeutic approach in diabetes and Alzheimer's disease

J Biochem Mol Toxicol. 2019 Aug;33(8):e22340. doi: 10.1002/jbt.22340. Epub 2019 Apr 11.

Abstract

Multiple studies have been recorded on the synthesis and design of multi-aim anti-Alzheimer molecules. Using dual butyrylcholinesterase/acetylcholinesterase inhibitor molecules has attracted more interest in the therapy for Alzheimer's disease. In this study, a tannic acid compound showed excellent inhibitory effects against acetylcholine esterase (AChE), α-glycosidase, α-amylase, and butyrylcholinesterase (BChE). IC50 values of tannic acid obtained 11.9 nM against α-glycosidase and 3.3 nM against α-amylase, respectively. In contrast, Ki values were found of 50.96 ± 2.18 µM against AChE and 53.17 ± 4.47 µM against BChE. α-Glycosidase inhibitor compounds can be utilized as a novel group of antidiabetic drugs. By competitively decreasing glycosidase activity, these inhibitor molecules help to hamper the fast breakdown of sugar molecules and thereby control the blood sugar level.

Keywords: anticholinergics; antidiabetic; enzyme inhibition; metabolic enzymes; tannic acid.

MeSH terms

  • Acetylcholinesterase / drug effects
  • Alzheimer Disease / drug therapy*
  • Amylases / drug effects
  • Antioxidants / pharmacology*
  • Butyrylcholinesterase / drug effects
  • Diabetes Mellitus / drug therapy*
  • Drug Discovery*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Tannins / pharmacology*
  • alpha-Glucosidases / drug effects

Substances

  • Antioxidants
  • Enzyme Inhibitors
  • Tannins
  • Acetylcholinesterase
  • Butyrylcholinesterase
  • Amylases
  • alpha-Glucosidases